(BW Healthwire)–April 18, 2002—Xencor’s President and CEO, Dr. Bassil Dahiyat Chairs Panel at CALBIOsummit 2002

(BW Healthwire)–May 29, 2002—Xencor’s Protein Design Technology Provides Superior Control and Flexibility in Biotherapeutic Creation

Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier (BW Healthwire)–June 04, 2002—Xencor’s Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in room 701A. Monrovia, CA – Xencor, a drug discovery company

Xencor Reaches Research Milestone (BW Healthwire)–June 17, 2002—Monrovia, CA – Xencor today announced that it has reached a major milestone in its research agreement with Syngenta’s (NYSE: SYT) Torrey Mesa Research Institute (TMRI). In just six months, half the time agreed upon, Xencor has created

(BW Healthwire)–October 09, 2002—Grant to Support the Rational Design of Non-immunogenic Proteins

Bassil Dahiyat Named One of the World’s Top Young Innovators by Technology Review, MIT’s Magazine of Innovation. Dahiyat To Be Honored September 24-25 at The Emerging Technologies Conference at MIT

Chromos and Xencor announce agreement for use of the ACE System to produce biologics. Burnaby, British Columbia, Canada and Monrovia, California, United States – Chromos Molecular Systems Inc. (“Chromos“ TSX: CHR) and Xencor announced today that they have entered into a non-exclusive research

Xencor’s Protein Design Automation Technology Creates New Modality for Blocking TNF Alpha and Related Proteins

US Patent Issued for Novel G-CSF with Improved Pharmaceutical Properties Created by Protein Design Automation Technology

Stylli brings record of success in drug development and technology commercialization